Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Iloprost × Thoracic × Clear all

Phase

Phase 2 2 Phase NA 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lung Neoplasms 1

Interventions

pembrolizumab 138 Carboplatin 130 Cisplatin 123 Pemetrexed 96 Paclitaxel 78 Nivolumab 63 Radiotherapy 62 Docetaxel 58 Erlotinib Hydrochloride 57 Gemcitabine 51 Etoposide 39 osimertinib 38 durvalumab 38 Cyclophosphamide 38 Bevacizumab 38 atezolizumab 33 Cetuximab 29 Radiosurgery 23 130-nm albumin-bound paclitaxel 21 fludarabine 20 Magnetic Resonance Spectroscopy 20 Irinotecan 19 Specimen Handling 18 Radiation 18 Gefitinib 18 Everolimus 18 Vinorelbine 17 Taxes 17 Oxaliplatin 17 Ipilimumab 17

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02237183 2023-11-28

Iloprost in Preventing Lung Cancer in Former Smokers

National Cancer Institute (NCI)

Phase 1 Completed

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡